drugset / Trial / NCT03158025
A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users
RandomizedCrossoverQuadruple-blindTreatment
Summary
The primary purpose of this study is to evaluate the abuse potential of lemborexant (E2006) in comparison to placebo and 2 controls with known abuse potential (ie, zolpidem and suvorexant) with similar indications (zolpidem and suvorexant) or mechanisms of action (suvorexant).
Timeline
- Start
- 2017-04-19
- Primary completion
- 2018-07-04
- Completion
- 2018-07-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lemborexant | Small molecule | 10 mg | Oral |
| Subject | Lemborexant | Small molecule | 20 mg | Oral |
| Subject | Lemborexant | Small molecule | 30 mg | Oral |
| Subject | Suvorexant | Small molecule | 40 mg | Oral |
| Subject | Zolpidem | Small molecule | 30 mg | Oral |